HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Journal articles

Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein

Abstract : Hepatocellular carcinoma (HCC) represents similar to 90% of primary liver cancers and constitutes a major global health problem. Since a decade ago, the management of advanced disease that cannot be locally treated has mainly been based on multi-targeted antiangiogenic therapies. Some have demonstrated improvement in overall survival over best supportive care in first-and second-line treatment. This study focused on the efficacy of antiangiogenics in patients with advanced HCC and particularly the rising role of ramucirumab in patients with elevated alpha-fetoprotein at diagnosis.
Document type :
Journal articles
Complete list of metadata

https://hal-amu.archives-ouvertes.fr/hal-02143684
Contributor : Ghislain Bidaut Connect in order to contact the contributor
Submitted on : Wednesday, May 29, 2019 - 2:53:27 PM
Last modification on : Wednesday, November 3, 2021 - 9:48:20 AM

Links full text

Identifiers

Collections

Citation

Marine Gilabert, Jean-Luc Raoul. Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein. Journal of Hepatocellular Carcinoma, 2018, 5, pp.91-98. ⟨10.2147/JHC.S157413⟩. ⟨hal-02143684⟩

Share

Metrics

Record views

5